Skip to main content
12/18/2019

Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Continue Reading
8/6/2019

Bay Area Celiac Disease Study

Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.

Continue Reading
5/25/2017

Celiac Disease Study for Infants – Enroll Your Child Today!

The Center for Celiac Research at Massachusetts General Hospital, MassGeneral Hospital for Children, and the Celiac Research Program at Harvard Medical School, recently launched the Celiac Disease Genomic Environmental Microbiome and Metabolomic Study (CDGEMM) to understand the role that our genes, our gut microbiome, and environmental factors play in the development of celiac disease. 200 babies…

Continue Reading